Releases
SLP
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest Simulations Plus (SLP) stock and general news. This information may help you make smarter investment decisions.
About SLP
Simulations Plus, Inc. is a developer of drug discovery and development software for mechanistic modeling and simulation, for machine-learning-based prediction of properties of molecules from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. The Company offers its products and services through two business segments, which include Simulations Plus, Inc. and Cognigen Corporation. Cognigen Corporation is the subsidiary of the Company. Its pharmaceutical/chemistry software is used by various companies, such as pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies for use in the conduct of industry-based research. Its clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamics modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions.